These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 27626217)

  • 1. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
    Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
    Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
    Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
    Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.